基于MRI的评分系统用于预测淋巴结阳性乳腺癌新辅助化疗后腋窝缓解的多中心回顾性研究
本研究基于三家医院389例临床淋巴结阳性乳腺癌患者的新辅助化疗前后MRI及临床病理特征,构建并验证了一个包含7个预测因子的简化评分系统,用于术前预测腋窝病理完全缓解。该评分系统在训练集、内部验证集和外部验证集中的AUC分别为0.835、0.828和0.798,评分≥11分的患者腋窝pCR率达86%-100%。将评分系统与SLNB联合可将假阴性率从14.5%降至4.8%。
要点
- 评分系统包含7个预测因子:孕激素受体阴性(3分)、HER2阳性(2分)、NAC后临床T0-1期(2分)、NAC前乳腺肿瘤较高ADC值(1分)、NAC前无结周浸润(1分)、NAC后MRI无结周浸润(2分)、NAC后MRI瘤床无强化(2分)。
- 评分≥11分提示腋窝pCR率高(86%-100%),可辅助筛选适合降级腋窝手术的患者。
- 评分系统联合SLNB可降低假阴性率(从14.5%到4.8%),提高腋窝分期准确性。
关键影像表现/征象
- NAC后MRI显示瘤床无强化是腋窝pCR的预测因子(2分)。
- NAC前和NAC后MRI均显示无结周浸润是腋窝pCR的预测因子(分别1分和2分)。
- NAC前乳腺肿瘤ADC值较高是腋窝pCR的预测因子(1分)。
诊断标准与关键数值
- 评分系统总分≥11分时,腋窝pCR率为86%-100%。
- 评分系统在训练集、内部验证集和外部验证集中的AUC分别为0.835、0.828和0.798。
- 在模拟临床应用的测试队列中,四位不同放射科医师使用评分系统诊断腋窝pCR的准确率为80%-90%。
- 与单独SLNB相比,评分系统联合SLNB将假阴性率从14.5%降低至4.8%。
临床应用与阅片要点
- 阅片时需评估NAC后MRI瘤床强化情况、结周浸润的有无以及NAC前肿瘤ADC值,这些是评分系统的关键影像指标。
- 评分系统可用于术前预测腋窝pCR,辅助多学科团队决策是否降级腋窝手术。
- 联合SLNB可降低假阴性率,但需注意评分系统需结合临床病理特征综合应用。
局限性
- 回顾性研究设计可能存在选择偏倚。
- 样本来自三家医院,外部验证仍需更大规模多中心研究确认。
- 评分系统的预测性能在外部验证集中AUC为0.798,略低于训练集,需进一步优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To develop and validate a simplified scoring system by integrating MRI and clinicopathologic features for preoperative prediction of axillary pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in clinically node-positive breast cancer.
MATERIALS AND METHODS: A total of 389 patients from three hospitals were retrospectively analyzed. To identify independent predictors for axillary pCR, univariable and multivariable logistic regression analyses were performed on pre- and post-NAC MRI and clinicopathologic features. Then, a simplified scoring system was constructed based on regression coefficients of predictors in the multivariable model, and its predictive performance was assessed with the receiver operating characteristic curve and calibration curve. The added value of the scoring system for reducing false-negative rate (FNR) of the sentinel lymph node biopsy (SLNB) was also evaluated.
RESULTS: The simplified scoring system including seven predictors: progesterone receptor-negative (Three points), HER2-positive (Two points), post-NAC clinical T0-1 stage (Two points), pre-NAC higher ADC value of breast tumor (One point), absence of perinodal infiltration at pre-NAC (One point) and post-NAC MRI (Two points), and absence of enhancement in the tumor bed at post-NAC MRI (Two points), showed good calibration and discrimination, with AUCs of 0.835, 0.828 and 0.798 in the training, internal and external validation cohorts, respectively. The axillary pCR rates were increased with the total points of the scoring system, and patients with a score of ≥11 points had a pCR rate of 86%-100%. In test cohorts for simulating clinical application, the diagnostic accuracy for axillary pCR was 80%-90% among four different radiologists. Compared to standalone SLNB, combining the scoring system with SLNB reduced the FNR from 14.5% to 4.8%.
CONCLUSION: The clinicopathologic-image scoring system with good predictive performance for axillary pCR in clinically node-positive breast cancer, may guide axillary management after NAC and improve patient selection for de-escalating axillary surgery to reduce morbidity.
引用
- Huang, Shi, Mai, et al. An MRI-based Scoring System for Preoperative Prediction of Axillary Response to Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: A Multicenter Retrospective Study. Acad Radiol. 2022. PMID: 36280517. doi:10.1016/j.acra.2022.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。